Watch Longevity — peptide industry news, explained simply

Monday, May 4, 2026

Peptide industry news

placeholder

UPDATE45

CLINICAL TRIALLimited grounding

Asahi Kasei starts phase 1 trial of PeptiDream peptide drug By Investing.com - Investing.com Australia

Analysis

Asahi Kasei advancing a PeptiDream-derived peptide into Phase 1 signals continued validation of PeptiDream's discovery platform for partnered programs.

Asahi Kasei initiated a Phase 1 trial of a peptide drug from PeptiDream

Asahi Kasei PeptiDream

Peptide Therapy Research13d

Read

placeholder

UPDATE35

CLINICAL TRIALLimited grounding

Asahi Kasei starts phase 1 trial of PeptiDream peptide drug - Investing.com

Analysis

Asahi Kasei advances a PeptiDream-derived candidate into Phase 1, marking incremental pipeline progress for the Japanese peptide discovery platform.

Asahi Kasei initiated a Phase 1 trial of a PeptiDream-derived peptide drug

Asahi Kasei

Peptide Therapy Research13d

Read

Week in Review

Where the industry is moving

FDA moves to permanently shut compounded GLP-1 channel

FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, signaling no appetite for compounded GLP-1s and intensifying enforcement against compounders like Empower.

Where it leads

If finalized, branded supply from Lilly and Novo absorbs the redirected demand; the Empower ruling shows courts will still litigate compounders case-by-case rather than wholesale shutdown.

Based on 23 stories this week

Semaglutide loss-of-exclusivity begins in Canada

Health Canada cleared first and second generic semaglutides from Apotex and Dr. Reddy's, framed by observers as a G7 test case for Novo's Ozempic franchise; Novo simultaneously cut US list prices for Ozempic and Wegovy by up to 50%.

Where it leads

Generic entry in one major market plus a 50% US list-price cut points to accelerating margin compression on Novo's flagship franchise as more semaglutide generics queue globally.

Based on 17 stories this week

Obesity race fragments into pills, dual agonists, amylin

Lilly's oral Foundayo hit ~20,000 patients while reportedly trailing Novo's rebranded Ozempic pill; Boehringer/Zealand's survodutide posted 16.6% Phase 3 weight loss; Amgen launched MariTide switch trials and Lilly's CEO publicly jabbed AbbVie and Pfizer amylin programs.

Where it leads

GLP-1 monotherapy injectables are no longer the only battleground — competition is splintering into oral GLP-1s, GLP-1/glucagon dual agonists, monthly dosing, and amylin combos, with Lilly and Novo defending on multiple fronts at once.

Based on 25 stories this week

Drawn from 100 stories · Generated 6h ago

Inside

Providers

A curated index of vetted peptide sourcing partners — pricing, sourcing notes, and the deals worth your attention.

Read the dispatch →

Partner

Refills

Compounded GLP-1s, fast.

Starts at $159 with free same-day shipping
Telehealth consults & care coaching
No insurance needed

Reader offer

$100 off first order

Visit Refills

The Daily Wire

Critical news, in your inbox.

One email a day with the day's most important peptide-industry stories — explained in plain English. No filler.